- Home
- YXT vs PROK Comparison
YXT vs PROK Comparison
Compare YXT & PROK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- YXT
- PROK
- Stock Information
- Founded
- YXT 2011
- PROK 2015
- Country
- YXT China
- PROK United States
- Employees
- YXT N/A
- PROK N/A
- Industry
- YXT
- PROK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- YXT
- PROK Health Care
- Exchange
- YXT NYSE
- PROK Nasdaq
- Market Cap
- YXT 268.5M
- PROK 220.6M
- IPO Year
- YXT 2024
- PROK N/A
- Fundamental
- Price
- YXT $2.15
- PROK $2.00
- Analyst Decision
- YXT
- PROK Buy
- Analyst Count
- YXT 0
- PROK 5
- Target Price
- YXT N/A
- PROK $4.50
- AVG Volume (30 Days)
- YXT 20.9K
- PROK 355.2K
- Earning Date
- YXT 11-21-2024
- PROK 11-19-2024
- Dividend Yield
- YXT N/A
- PROK N/A
- EPS Growth
- YXT N/A
- PROK N/A
- EPS
- YXT N/A
- PROK N/A
- Revenue
- YXT $53,329,409.00
- PROK N/A
- Revenue This Year
- YXT N/A
- PROK N/A
- Revenue Next Year
- YXT N/A
- PROK N/A
- P/E Ratio
- YXT N/A
- PROK N/A
- Revenue Growth
- YXT N/A
- PROK N/A
- 52 Week Low
- YXT $2.05
- PROK $1.12
- 52 Week High
- YXT $11.00
- PROK $4.44
- Technical
- Relative Strength Index (RSI)
- YXT N/A
- PROK 59.01
- Support Level
- YXT N/A
- PROK $1.49
- Resistance Level
- YXT N/A
- PROK $1.83
- Average True Range (ATR)
- YXT 0.00
- PROK 0.12
- MACD
- YXT 0.00
- PROK 0.04
- Stochastic Oscillator
- YXT 0.00
- PROK 94.27
About YXT YXT.COM GROUP HOLDING LIMITED SPON ADS EA REP 3 CL A SHS
Yxt.Com Group Holding Ltd operates as a technology company. The company has created a SaaS model that integrates software and content, assisting customers in the digital transformation of corporate learning. The company operates in the People's Republic of China.
About PROK ProKidney Corp.
ProKidney Corp is a clinical-stage biotechnology company with a transformative proprietary cell therapy platform capable of treating multiple chronic kidney diseases using a patient's own cells isolated from the patient intended for treatment. Its lead product candidate, REACT (Renal Autologous Cell Therapy) is a disease-modifying cell therapy made from a patient's own renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of development program for severe diabetic kidney disease.